S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:TCON

TRACON Pharmaceuticals - TCON Stock Forecast, Price & News

$2.09
-0.12 (-5.43%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.09
▼
$2.30
50-Day Range
$1.30
▼
$2.22
52-Week Range
$1.24
▼
$4.49
Volume
41,283 shs
Average Volume
96,986 shs
Market Capitalization
$44.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

TRACON Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
373.9% Upside
$10.00 Price Target
Short Interest
Healthy
0.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of TRACON Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$1.15 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.87) to ($1.15) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

330th out of 1,116 stocks

Biological Products, Except Diagnostic Industry

51st out of 178 stocks

See Top Rated MarketRank™ Stocks Here
TCON stock logo

About TRACON Pharmaceuticals (NASDAQ:TCON) Stock

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of TRACON Pharmaceuticals in a report on Sunday, August 14th. They issued a "sell" rating for the company.

TRACON Pharmaceuticals Stock Performance

Shares of TRACON Pharmaceuticals stock opened at $2.21 on Friday. The company has a market capitalization of $47.34 million, a PE ratio of -1.41 and a beta of 1.47. The company has a 50-day simple moving average of $1.79 and a two-hundred day simple moving average of $2.12. TRACON Pharmaceuticals has a one year low of $1.24 and a one year high of $4.49.

Insiders Place Their Bets

In other news, major shareholder Opaleye Management Inc. bought 841,989 shares of TRACON Pharmaceuticals stock in a transaction on Tuesday, June 21st. The stock was acquired at an average cost of $1.31 per share, for a total transaction of $1,103,005.59. Following the completion of the acquisition, the insider now owns 3,776,589 shares of the company's stock, valued at approximately $4,947,331.59. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders bought 870,349 shares of company stock worth $1,149,698. 3.54% of the stock is owned by corporate insiders.

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Stock News Headlines

August 16, 2022 | americanbankingnews.com
TRACON Pharmaceuticals, Inc. to Post Q3 2022 Earnings of ($0.31) Per Share, Jefferies Financial Group Forecasts (NASDAQ:TCON)
August 15, 2022 | americanbankingnews.com
TRACON Pharmaceuticals (NASDAQ:TCON) Receives New Coverage from Analysts at StockNews.com
August 14, 2022 | americanbankingnews.com
Analysts Offer Predictions for TRACON Pharmaceuticals, Inc.'s FY2026 Earnings (NASDAQ:TCON)
August 10, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals ends 2Q with strong cash runway to support key trials
August 10, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals says ENVASARC trial gets recommendation to proceed as planned
August 9, 2022 | americanbankingnews.com
TRACON Pharmaceuticals (TCON) Scheduled to Post Quarterly Earnings on Wednesday
August 8, 2022 | msn.com
TRACON Seeks FDA Nod For Initial-Stage Tissue Cancer Study
August 8, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals submits new drug application for the treatment of sarcoma patients in combination with envafolimab
August 8, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
August 8, 2022 | americanbankingnews.com
TRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by Analysts at StockNews.com
August 5, 2022 | americanbankingnews.com
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Short Interest Update
July 31, 2022 | americanbankingnews.com
TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.com
July 27, 2022 | finance.yahoo.com
TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022
July 26, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals announces milestone dosing of 36th patient in ENVASARC pivotal trial
July 26, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals enrols 36th patient at ENVASARC trial triggering 4Q interim efficacy analysis
July 26, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
June 2, 2022 | finance.yahoo.com
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 12, 2022 | seekingalpha.com
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q1 2022 Results - Earnings Call Transcript
May 11, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 4, 2022 | finance.yahoo.com
TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022
April 19, 2022 | seekingalpha.com
TRACON Pharma says amended protocol for ENVASARC trial approved at all 30 clinical sites
April 19, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals receives amended ENVASARC protocol approval for its US and UK clinical sites
April 19, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.
March 23, 2022 | finance.yahoo.com
TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference
See More Headlines
Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Company Calendar

Last Earnings
11/03/2021
Today
8/19/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCON
CUSIP
N/A
CIK
1394319
Web
www.traconpharma.com
Phone
(858) 550-0780
Fax
858-550-0786
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+378.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-28,670,000.00
Net Margins
N/A
Pretax Margin
-9,559.54%
Return on Equity
-338.27%
Return on Assets
-129.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.17
Quick Ratio
1.17

Sales & Book Value

Annual Sales
$350,000.00
Price / Sales
127.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.12 per share
Price / Book
17.42

Miscellaneous

Outstanding Shares
21,422,000
Free Float
20,664,000
Market Cap
$44.77 million
Optionable
Not Optionable
Beta
1.47

Key Executives

  • Dr. Charles P. Theuer M.D. (Age 58)
    Ph.D., CEO, Pres & Director
    Comp: $827.53k
  • Mr. Scott B. Brown CPA (Age 41)
    M.S., Chief Financial Officer
    Comp: $459.21k
  • Mr. Mark C. Wiggins M.B.A. (Age 66)
    Chief Bus. Officer
    Comp: $506.25k
  • Ms. Bonne Adams (Age 45)
    Exec. VP of Clinical Operations
  • Mr. Shahe Garabedian
    Sr. VP & Head of Quality Assurance
  • Dr. James L. Freddo (Age 67)
    Chief Medical Officer
  • Mr. Ya Huang
    Exec. Director of Statistical Programming
  • Dr. Brenda Marczi Pharm.D.
    Pharmd Mba, Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TCON Stock - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCON shares.
View TCON analyst ratings or view top-rated stocks.

What is TRACON Pharmaceuticals' stock price forecast for 2022?

1 Wall Street research analysts have issued 1 year price targets for TRACON Pharmaceuticals' shares. Their TCON share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 352.5% from the stock's current price.
View analysts price targets for TCON or view top-rated stocks among Wall Street analysts.

How have TCON shares performed in 2022?

TRACON Pharmaceuticals' stock was trading at $2.77 at the beginning of 2022. Since then, TCON shares have decreased by 20.2% and is now trading at $2.21.
View the best growth stocks for 2022 here.

When is TRACON Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our TCON earnings forecast.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.06. During the same period last year, the firm earned ($0.38) EPS.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (20.37%), Ikarian Capital LLC (13.77%), Millennium Management LLC (0.37%), Renaissance Technologies LLC (0.26%) and CSS LLC IL (0.12%). Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $2.21.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $47.34 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-28,670,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786.

This page (NASDAQ:TCON) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.